TY  - JOUR

T1  - A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients with bone metastases.

JO  - Journal of Clinical Oncology

PY  - 2016/05/20

AU  - Coleman RE

AU  - Li R

AU  - Sawhney AG

AU  - Petrenciuc O

AU  - Rugo HS

ED  - 

DO  - DOI: 10.1200/jco.2016.34.15_suppl.tps622

PB  - American Society of Clinical Oncology (ASCO)

VL  - 34

IS  - 15_suppl

SP  - TPS622

EP  - TPS622

Y2  - 2025/10/10

ER  -